Skip to content
Back to meeting Original
Stephen V Liu, MD· @StephenVLiu · X·· 1 day agoScore70
Body

Simultaneous publication @NEJM of #ESMO26 presentation from Dr. Shun Lu. Osimertinib + savolitinib superior to chemo in EGFR+ NSCLC post osimertinib with MET overexpression and/or amp: 338 randomized / 1746 screened: PFS 7.6 vs 5.4m, HR 0.55, OS HR 0.68
https://www.nejm.org/doi/full/10.1056/NEJMoa2611335

220 views · 8 likes · 3 reposts · 0 replies

Source: Stephen V Liu, MD · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.